Key Stats for IQVIA Stock
- This Week Performance: 8%
- 52-Week Range: $134.7 to $247.1
- Current Price: $178.1
What Happened?
IQVIA’s proprietary data moat and strategic acquisition of Charles River’s drug discovery assets reframe the company from a threatened CRO into AI’s most indispensable life sciences partner, with shares recovering to $178.8.
On February 25, IQVIA signed an agreement to acquire five European drug discovery sites from Charles River Laboratories for $145 million, immediately lifting shares 2.3% premarket to $167.8.
The acquired assets generated $144 million in 2025 revenue and add a small-molecule AI platform and New Approach Methodologies, expanding IQVIA’s end-to-end drug discovery capabilities from target identification through early safety assessment.
Consequently, the market is beginning to re-rate IQVIA from an AI-disruption target into the life sciences industry’s essential AI infrastructure layer, with incoming CFO Mike Fedock noting the stock trades at just 13x earnings versus its historical high-teens to low-20s range.
Chairman and CEO Ari Bousbib stated on the Q4 earnings call that “AI agentification is a positive for our business across both clinical and commercial,” underscoring IQVIA’s deployment of 150+ agents across 30+ use cases built on 71 years of proprietary data.
Further reinforcing conviction, TD Cowen maintained coverage with a $174 price target, while Barclays separately noted AI represents an opportunity rather than a threat for contract research organizations holding irreplaceable proprietary data assets.
Over the next 3 to 5 years, IQVIA’s combination of 150,000 global data feeds, an expanding drug discovery platform, and agentic AI infrastructure positions it to capture an outsized share of pharma’s accelerating R&D outsourcing wave.
Wall Street’s Take on IQV Stock
IQVIA’s $145 million acquisition of Charles River’s drug discovery assets directly expands its end-to-end platform, strengthening the revenue runway into 2026 and beyond.
Underlying fundamentals support that expansion, with 2026 revenue estimated at $17.2 billion (+5.7% YoY) and normalized EPS climbing to $12.7 (+6.5% YoY).
Currently, 16 analysts rate IQV a Buy and 3 rate it Outperform, with a mean price target of $236.3, implying 32.1% upside from $178.8.
Notably, the target range spans $174 to $287, where the high case hinges on AI monetization acceleration and the low case reflects continued multiple compression from macro uncertainty.
What Does the Valuation Model Say?
TIKR’s mid-case valuation model targets $301.6 by December 2030, implying a 68.7% total return and an 11.4% annualized IRR from current levels.
The market prices IQV at just 13x earnings, well below its historical high-teens to low-20s range, making the discount undeniable.
IQVIA processes more daily transactions than the NYSE and supplies 75% of pharma’s global data, yet trades like a disruption victim.
Incoming CFO Mike Fedock publicly called the stock a “screaming buy” at Citi’s Access Day on February 26, signaling deep management conviction.
However, if AI-driven margin compression erodes the consulting segment faster than expected, the $100 million revenue-at-risk estimate could prove too conservative.
Investors should watch Q1 2026 earnings closely, as book-to-bill and Commercial Solutions growth will confirm whether the re-rating has real legs.
IQV is undervalued at 13x earnings with a $236.3 consensus target; the Charles River deal and AI monetization are the inflection to watch.
Should You Invest in IQVIA Holdings, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up IQV stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track IQVIA Holdings, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze IQV stock on TIKR for Free →
